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Abstract
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints for amphotericin
B for Candida spp. This Technical Note is based on the
EUCAST amphotericin B rationale document (available on the
EUCAST website: http://www.eucast.org). Species-speciﬁc
breakpoints for C. albicans, C. glabrata, C. krusei, C. parapsilosis
and C. tropicalis are S: MIC £1 mg/L, R: MIC > 1 mg/L. There
are insufﬁcient data to set breakpoints for other species. The
breakpoints are based upon pharmacokinetic data, epidemio-
logical cut-ff values and clinical experience. Breakpoints will be
reviewed regularly.
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Introduction
Amphotericin B is a polyene antifungal agent that is active
against yeasts and moulds. In Europe, it is available in four dif-
ferent parental formulations, including amphotericin B deoxy-
cholate and three lipid formulations. The active compound is
identical but the pharmacokinetics and toxicity proﬁles vary
from formulation to formulation. The licensed indications for
each formulation are as follows: amphotericin B deoxycholate
(AMB-DC), serious infections due to amphotericin B-suscepti-
ble fungi; amphotericin B lipid complex (ABLC), ﬁrst-line
treatment of systemic Candida infections; amphotericin B col-
loidal dispersion (ABCD), serious infections due to amphoter-
icin-susceptible fungi, where amphotericin B deoxycholate
is contraindicated or has failed; liposomal amphotericn B
(L-amphotericin B), treatment of invasive fungal infections due
to amphotericin B-susceptible fungi, and treatment of sus-
pected fungal infection in neutropenic patients with persistent
fever despite antibacterial treatment for 5–7 days.
The European Committee on Antimicrobial Susceptibility
Testing-Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has determined breakpoints of amphoteri-
cin B for Candida spp. This Technical Note is based on the
EUCAST amphotericin B rationale document (available on
the EUCAST website: http://www.eucast.org). The rationale
document includes more detail and published references
related to the selection of EUCAST-AFST breakpoints
(http://www.srga.org/eucastwt/MICTAB/EUCAST%20clinical%
20MIC%20breakpoints%20-%20antimicrobials%20for%20
Candida%20infections.htm).
The breakpoints are based upon the following dosages
administered intravenously: amphotericin B, 0.6–1 mg/kg/
day; liposomal amphotericin, 3 mg/kg/day; amphotericin B
lipid complex (ABLC) and amphotericin B colloidal disper-
sion (ABCD), 3–5 mg/kg/day. Breakpoints were established
using MIC values from multiple laboratories. Wild-type
isolates of each of the ﬁve common species (C. albicans,
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C. glabrata, C. krusei, C. parapsilosis and C. tropicalis) exhibit
MICs £ 1 mg/L.
The EUCAST breakpoints (Table 1) are based on pharma-
cokinetic [1–7] and microbiological data and clinical experi-
ence [8–15]. For most studies clinical outcome data were
not speciﬁed for the individual Candida species. Combining
the studies that provided such data [8,12,14], failure rates
were as follows. For L-amphotericin B the overall failure rate
was 9% (16/174) and for individual species: C. albicans 11%
(7/73), C. tropicalis 4% (2/45), C. parapsilosis 10% (3/29),
C. glabrata 20% (3/15) and C. krusei 20% (1/5). For ampho-
tericin B deoxycholate the overall failure rate was 38% (44/
115) and for individual species: C. albicans 8% and C. krusei
3%. These data indicate that the ﬁve commonest species are
good targets for all amphotericin B formulations. There are
too few data to enable any deﬁnitive recommendation to be
made for species other than those addressed in this docu-
ment. None of the clinical studies estimated MICs using
EUCAST methodology so a direct correlation between in vi-
tro MICs and clinical outcome is currently not possible. Fur-
thermore, there is no clinical experience with isolates with
acquired resistance mechanisms; hence the breakpoints are
based upon epidemiological cut-off values.
Transparency Declaration
The authors do not have any potential conﬂicts of interests
related particularly to this paper. Otherwise, MCA has
received research grants and acted as speaker for Astellas,
Gilead, MSD and Pﬁzer, and been a consultant for Gilead,
MSD and Pcovery. JLRT has received grant support from
Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme,
Pﬁzer, Schering Plough, Soria Melguizo SA, the European
Union, the Spanish Agency for International Cooperation,
the Spanish Ministry of Culture and Education, The Spanish
Health Research Fund, The Instituto de Salud Carlos III, The
Ramon Areces Foundation and The Mutua Madrilen˜a Foun-
dation. He has been an advisor/consultant to the Panameri-
can Health Organization, Gilead Sciences, Merck Sharp and
Dohme, Mycognostica, Pﬁzer and Schering Plough. He has
been paid for talks on behalf of Gilead Sciences, Merck Sharp
and Dohme, Pﬁzer, and Schering Plough. CLF has research
grants, consultant and/or speakers bureau, for Pﬁzer, Astel-
las, Gilead and Merck. MCE has received grant support from
Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp
and Dohme, Pﬁzer, Schering Plough, Soria Melguizo SA, the
European Union, the ALBAN program, the Spanish Agency
for International Cooperation, the Spanish Ministry of Cul-
ture and Education, The Spanish Health Research Fund, The
Instituto de Salud Carlos III, The Ramon Areces Foundation
and The Mutua Madrilen˜a Foundation. He has been an advi-
sor/consultant to the Panamerican Health Organization,
Gilead Sciences, Merck Sharp and Dohme, Pﬁzer and Scher-
ing Plough. He has been paid for talks on behalf of Gilead
Sciences, Merck Sharp and Dohme, Pﬁzer and Schering
Plough. PD has been a consultant for Astellas, Gilead, Merck,
Pﬁzer, received research grants from Pﬁzer and is on the
speakers bureau for Gilead, Merck and Pﬁzer. WWH has
research grants, consultant and/or speakers bureau, for Pﬁz-
er, Astellas, Gilead, Merck, Vectura and F2G.
References
1. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ.
Pharmacokinetics, excretion, and mass balance of liposomal ampho-
tericn B (AmBisome) and amphotericin B deoxycholate in humans.
Antimicrob Agents Chemother 2002; 46: 828–833.
2. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh
TJ. Plasma protein binding of amphotericin B and pharmacokinetics
of bound versus unbound amphotericin B after administration of
intravenous liposomal amphotericin B (AmBisome) and amphoteri-
cin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834–
840.
3. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharma-
cokinetics of high-dose liposomal amphotericin B (AmBisome) in
patients infected with Aspergillus species and other ﬁlamentous fungi:
maximum tolerated dose study. Antimicrob Agents Chemother 2001;
45: 3487–3496.
4. Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinet-
ics and buccal mucosal concentrations of a 15 milligram per kilogram
of body weight total dose of liposomal amphotericin B administered
as a single dose (15 mg/kg), weekly dose (7.5 mg/kg), or daily dose
(1 mg/kg) in peripheral stem cell transplant patients. Antimicrob Agents
Chemother 2009; 53: 3664–3674.
5. Adedoyin A, Bernardo JF, Swenson CE et al. Pharmacokinetic proﬁle
of ABELECET (amphotericin B lipid complex injection): combined
experiences from phase I and phase II studies. Antimicrob Agents Che-
mother 1997; 41: 2201–2208.
6. Adedoyin A, Swenson CE, Bolcsak LE et al. A pharmacokinetic study
of amphotericin B lipid complex injection (Abelecet) in patients with
deﬁnite or probable systemic fungal infections. Antimicrob Agents
Chemother 2000; 44: 2900–2902.
TABLE 1. EUCAST MIC breakpoints for amphotericin B
Species
Species-related
breakpoints (mg/L)
C. albicans S £ 1 R > 1
C. glabrata S £ 1 R > 1
C. parapsilosis S £ 1 R > 1
C. tropicalis S £ 1 R > 1
C. krusei S £ 1 R > 1
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